All In Biotech

Drug Trial Radar · NCT06789289

A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic Characteristics of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

256

Actual

Start

Mar 17, 2025

Primary completion

Mar 17, 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It is anticipated that 256 subjects will be enrolled.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • TQC2938 injectionDrug

    TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.

  • TQC2938 injection PlaceboDrug

    TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The annualized incidence rate of moderate to severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD within 24 weeksTime frame: Baseline up to week 24

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • An Hui Chest Hospital

    Hefei, Anhui, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Peolpe's Hospital Of Chongqing Banan District

    Chongqing, Chongqing Municipality, China

  • Shunde Hospital Of Southern Medical University

    Foshan, Guangdong, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • Liuzhou municipal liutie central hospital

    Liuzhou, Guangxi, China

  • The First People' Hospital Of YuLin

    Yulin, Guangxi, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • Xingtai People's Hospital

    Xingtai, Hebei, China

  • The second hospital of hebei medical university

    Shijiazhuang, Heibei, China

  • The First Affiliated Hospital of Jiamusi University

    Jiamusi, Heilongjiang, China

  • The First Hospital of Qiqihar

    Qiqihar, Heilongjiang, China

  • Puyang Oilfield General Hospital

    Puyang, Henan, China

  • The First People's Hospital of Xinxiang City

    Xinxiang, Henan, China

  • Yongcheng People's Hospital

    Yongcheng, Henan, China

  • Henan Chest Hospital

    Zhengzhou, Henan, China

  • The second xiangya hospital of central south university

    Changsha, Hunan, China

  • Shaoyang Central Hospital

    Shaoyang, Hunan, China

  • The Affiliated Hospital of Mongolia Medical College

    Hohhot, Inner Mongolia, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • Jiangxi Provincal People's Hospital

    Nanchang, Jiangxi, China

  • Meihekou Central Hospital

    Meihekou, Jilin, China

  • Siping Central People's Hospital

    Siping, Jilin, China

  • Heze Municipal Hospital

    Heze, Shandong, China

  • Weifang NO.2 People' Hospital

    Weifang, Shandong, China

  • Shanghai JiaoTong University of medicine Ruijin Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Linfen Central Hospital

    Linfen, Shanxi, China

  • Xi'An International Medicl Center Hospital

    Xi’an, Shanxi, China

  • Affiliated Hospital Of ChengDu University

    Chengdu, Sichuan, China

  • Leshan People's Hospital

    Leshan, Sichuan, China

  • Suining Central Hospital

    Suining, Sichuan, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • The Fourth Central Hospital of Tianjin

    Tianjin, Tianjin Municipality, China

  • The Third People's Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang, China

  • Jinhua Municipal Centeral Hospital Medical Group

    Jinhua, Zhejiang, China

  • The First Affiliated Hospitial Of Ningbo University

    Ningbo, Zhejiang, China

  • Taizhou Hospital Of Zhejiang Province

    Taizhou, Zhejiang, China

  • The 2th School of Medicine ,WMU/The 2th affiliated Hospital and Yuying Children's Hospital of WMU

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.